Open Access

Diagnosis and management of interstitial lung disease

Translational Respiratory Medicine20142:4

DOI: 10.1186/2213-0802-2-4

Received: 30 September 2013

Accepted: 17 December 2013

Published: 13 February 2014

Abstract

The complex tasks of making a confident diagnosis of a specific form of interstitial lung disease (ILD) and formulating a patient-centered, personalized management plan in an attempt to achieve remission or stabilization of the disease process can pose formidable challenges to clinicians. When patients are evaluated for suspected ILD, an accurate diagnosis of the specific form of ILD that a patient has developed must be made to provide the patient with useful prognostic information and to formulate an appropriate management plan that can relieve symptoms and restore or significantly improve quality of life. A well-performed patient history and physical examination provides invaluable information that can be combined with appropriate laboratory testing, imaging, and, if needed, tissue biopsy to reach a confident ILD diagnosis, and high-resolution computed tomography (HRCT) of the thorax is usually a key component of the diagnostic evaluation. If treatment is indicated, many forms of ILD can respond significantly to immunosuppressive anti-inflammatory therapies. However, ILD accompanied by extensive fibrosis may be difficult to treat, and the identification of an effective pharmacologic therapy for idiopathic pulmonary fibrosis (IPF) has remained elusive despite the completion of many phase 3 clinical trials over the past decade. Nonetheless, patients with IPF or advanced forms of non-IPF ILD can benefit significantly from detection and treatment of various co-morbid conditions that are often found in patients (especially the elderly patient), and supportive care (oxygen therapy, pulmonary rehabilitation) can have a beneficial impact on quality of life and symptom palliation. Finally, lung transplantation is an option for patients with progressive, advanced disease that does not respond to other therapies, but only a relatively small subset of patients with end-stage ILD are able to meet wait listing requirements and eventually undergo successful lung transplantation.

Keywords

Interstitial lung disease Idiopathic pulmonary fibrosis Therapeutics Diagnosis

Introduction

Well over one hundred different forms of interstitial lung disease (ILD) have been described (see Table 1 for major categories). These diffuse infiltrative lung disorders are typically characterized by the presence of inflammation and altered lung interstitium, and specific forms of ILD can be differentiated from one another when clinical data, radiologic imaging, and pathologic findings (if lung biopsy is needed) are combined to reach a confident diagnosis[1, 2]. The histopathologic changes in the lungs of patients with ILD can range from granulomatous inflammation without parenchymal fibrosis in patients with sarcoidosis to extensive pulmonary fibrosis with architectural distortion of the lung in patients with idiopathic pulmonary fibrosis (IPF). Some forms of ILD have been linked to specific genetic abnormalities (e.g. Hermansky-Pudlak syndrome, familial pulmonary fibrosis), and a number of gene variants have been associated with an increased risk to develop ILD disorders such as IPF, sarcoidosis, or chronic beryllium disease (CBD). Interstitial lung disease can also complicate connective tissue disorders (CTD), and lung histopathologic changes can have features of usual interstitial pneumonia (UIP) or non-specific interstitial pneumonia (NSIP) patterns in CTD-associated ILD[3].
Table 1

Interstitial lung disorders: major categories

• Idiopathic interstitial pneumonia

• Sarcoidosis

o Idiopathic pulmonary   fibrosis (IPF)

• Hypersensitivity pneumonitis

o Non-specific interstitial   pneumonia (NSIP)

• Iatrogenic pneumonitis/fibrosis (drug-induced ILD, radiation injury)

o Cryptogenic organizing   pneumonia (COP)

• Eosinophilic ILD (e.g. eosinophilic pneumonia)

o Respiratory bronchiolitis   interstitial lung disease (RBILD)

• Occupational lung disease

o Desquamative interstitial   pneumonia (DIP)

• Inherited disorders (e.g. familial pulmonary fibrosis, Hermansky-Pudlak syndrome)

o Acute interstitial   pneumonia (AIP)

• Primary disorders (e.g. pulmonary Langerhans cell histiocytosis)

o Lymphoid interstitial   pneumonia (LIP)

 

• Connective tissue disease-associated interstitial lung disease (CTD-ILD)

 

Successful management of patients with ILD is dependent upon establishing an accurate and specific diagnosis[1, 2]. Because various forms of ILD such as IPF, non-IPF forms of idiopathic interstitial pneumonia (IIP), CTD-ILD, and hypersensitivity pneumonitis (HP) can have similar clinical presentations, patients with suspected ILD must undergo an evaluation that adequately establishes a confident diagnosis of a specific ILD, as treatment and various management decisions are diagnosis-specific and may vary considerably according to the specific form of ILD that is diagnosed. This manuscript will focus on[1] the appropriate steps that are required to make an accurate diagnosis of specific types of ILD,[2] general approaches to disease monitoring and management, and (3) therapies for specific disorders such as IPF.

Review

Clinical evaluation

A thorough and comprehensive history may provide invaluable information that can suggest certain entities and provide suspicion that a patient may have a specific diagnosis such as hypersensitivity pneumonitis (HP) or CTD-ILD (Table 2). Additional clues to an ultimate diagnosis can be provided by pulmonary and extra-pulmonary physical examination findings (Table 3), and the differential diagnosis can be considerably narrowed when key elements of the patient interview and physical examination findings are combined with appropriate measurements of lung function, specific blood tests (Table 4) such as autoimmune serologies to assist in the detection of CTD if such are indicated, extra-pulmonary tissue sampling (e.g. lymph node or skin biopsy), and thoracic imaging.
Table 2

Clues from the initial evaluation that suggest specific types of ILD

History elicited

Frequently associated ILD or complications of ILD

Rapid onset and worsening

AIP

Infection

Acute HP, acute EP

Drug reaction

COP

CTD (e.g. acute lupus pneumonitis)

DAH (e.g. GPS)

Smoking

RB-ILD, DIP, PLCH

Occupation: Pipefitter, foundry worker, coal miner,

Pneumoconiosis

Pneumotoxic drug exposure

Drug-induced ILD

Hemoptysis

DAH, pulmonary capillaritis, pulmonary venoocclusive disease, LAM

Superimposed complications (e.g. pulmonary emboli, lung neoplasm)

Pleurisy

CTD (SLE, RA)

Wheezing

HP, EP

Eye symptoms

CTD, sarcoidosis, PAG

Impaired vision combined with albinism & Puerto Rican heritage

HPS

Rash

Sarcoidosis, CTD

Exposure to organic antigens at home or at work (e.g. birds, grain dust, humidifiers, visible molds, hot tubs,etc.)

HP

Occupational ILD

Abnormal GER, GERD, dysphagia

CTD (especially scleroderma), IPF

Sicca symptoms

Sjögren’s disease

Raynaud’s phenomenon

CTD

Arthralgias, arthritis

CTD, sarcoidosis

Myalgias, muscle weakness

DM-PM

Morning stiffness

RA, CTD

Age >70 years

IPF > other ILD if HRCT suspicious for IIP

AIP = acute interstitial pneumonia; COP = cryptogenic organizing pneumonia; CTD = connective tissue disease; DAH = diffuse alveolar hemorrhage; DM-PM = dermatopolymyositis; EP = eosinophilic pneumonia; GER = gastroesophageal reflux; GERD = gastroesophageal reflux disease; GPS = Goodpasture’s syndrome; HP = hypersensitivity pneumonitis; HPS = Hermansky-Pudlak syndrome; IIP = idiopathic interstitial pneumonia; IPF = idiopathic pulmonary fibrosis; LAM = lymphangioleiomyomatosis; PAG = polyangiitis with granulomatosis; PLCH = pulmonary Langerhans cell histiocytosis; SLE = systemic lupus erythematosus; RA = rheumatoid arthritis.

Reprinted with permission from Interstitial Lung Disease: A Practical Approach. Meyer KC, Raghu G: Patient evaluation. Second Edition, New York: Springer; 2011:3–16.

Table 3

Clues from the physical examination and their disease associations

Organ system

Finding

Associated ILD or its complications

Lung

Velcro crackles

IPF, asbestosis > > other

Squeaks

HP, bronchiolitis

Pleural rub

RA, SLE

Skin

Erythema nodosum

Sarcoidosis, CTD, Behçet’s disease

Maculopapular rash

CVD, drugs, sarcoidosis, amyloid

Heliotrope rash

DM-PM

Gottron’s papules

DM-PM

Café-au-lait spots

Neurofibromatosis

Albinism

HPS

Telangiectasia

Scleroderma

Calcinosis

Scleroderma, DM-PM

Subcutaneous nodules

RA, neurofibromatosis, vasculitis

Cutaneous vasculitis

PAG, RA, MPA, SLE, drug reaction

Mechanic’s hands

DM-PM

Tight skin/ulcerations over digits

Scleroderma

Eyes

Uveitis

Sarcoidosis, Behçet’s disease, AS

Scleritis

SLE, scleroderma, sarcoidosis, PAG

Keratoconjunctivitis sicca

Sjögren’s disease, CTD

Lacrimal gland enlargement

Sarcoidosis

Horizontal nystagmus

HPS

Salivary glands

Enlarged

Sjögren’s disease, sarcoidosis

Lymphatic

Lymphadenopathy

Sarcoidosis, lymphangitic CA, lymphoma

Reticuloendothelial

Hepatosplenomegaly

Sarcoidosis, LIP, CTD, EG, amyloid, lymphoma

Musculoskeletal

Muscle weakness, myositis

CTD (especially DM-PM), sarcoidosis

Synovitis, arthritis

CTD, sarcoidosis

Nervous system

Neurologic dysfunction

Sarcoidosis, lymphangitic CA, NF, TS, CTD, PAG, MPA

Cardiovascular

Systemic hypertension

CTD, GPS, PAG, MPA, NF

Prominent P2

Suggests secondary PH (IPF, CTD, end stage sarcoidosis)

Pericardial rub

Sarcoidosis, SLE

Extremities

Digital clubbing

IPF, asbestosis > chronic HP, DIP > other fibrotic ILD

Raynaud’s phenomenon

CTD

AS = ankylosing spondylitis; CA = cancer; CTD = connective tissue disease; DAH = diffuse alveolar hemorrhage; DM-PM = dermatopolymyositis; GPS = Goodpasture’s syndrome; HP = hypersensitivity pneumonitis; HPS = Hermansky-Pudlak syndrome; LAM = lymphangioleiomyomatosis; LCH = Langerhans cell histiocytosis; LIP = lymphoid interstitial pneumonia; MPA = microscopic polyangiitis; NF = neurofibromatosis; P2 = auscultated pulmonic valve closure sound; PAG = polyangiitis with granulomatosis; PH = pulmonary hypertension; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; TS = tuberous sclerosis.

Reprinted with permission from Interstitial Lung Disease: A Practical Approach. Meyer KC, Raghu G: Patient evaluation. Second Edition, New York: Springer; 2011:3–16.

Table 4

Clues for specific diagnoses from blood and urine testing

Laboratory test

Abnormal result

Suggested disorder

CBC

Microcytic anemia

Occult pulmonary hemorrhage

Normocytic anemia

CTD, chronic disease

Leukocytosis

Infection, hematologic malignancy

Eosinophilia

Eosinophilic pneumonia, drug toxicity

Thrombocytopenia

CTD, sarcoidosis

Calcium

Hypercalcemia

Sarcoidosis

Creatinine

CTD, pulmonary-renal syndrome, sarcoidosis; amyloidosis

Liver function

↑ GGT, ALT, AST

Sarcoidosis, amyloidosis, CTD (polymyositis)

Urine

Abnormal sediment with RBC casts and/or dysmorphic RBCs

Vasculitis (CTD, PAG, GPS, MPA)

Muscle enzymes

↑Increased CK, aldolase

PM, DM-PM

Angiotensin Converting Enzyme (ACE)

Sarcoidosis (non-specific; can be increased in other ILD)

Lymphocyte proliferation

Stimulated by beryllium

CBD

Serum antibodies

↓ Quantitative immunoglobulins

Immunodeficiency (CVID)

↑ ANA, RF, anti-CCP

CTD, RA

↑ C-ANCA

PAG

↑ P-ANCA

CTD, vasculitis

↑ anti-GBM

GPS

Positive specific precipitin

Supportive of HP

↑ anti-Jo-1 or other anti-synthetase autoantibodies

PM, DM-PM

↑ SS-A, SS-B

Sjögren’s syndrome

CBD = chronic beryllium diseases; COP = cryptogenic organizing pneumonia; CTD = connective tissue disease; CVID = common variable immunodeficiency; DAH = diffuse alveolar hemorrhage; DM-PM = dermatopolymyositis; DIP = desquamative interstitial pneumonia; GPS = Goodpasture’s syndrome; HP = hypersensitivity pneumonitis; MPA = microscopic polyangiitis; PM = polymyositis; PAG = polyangiitis with granulomatosis; RA = rheumatoid arthritis;

Reprinted with permission from Interstitial Lung Disease: A Practical Approach. Meyer KC, Raghu G: Patient evaluation. Second Edition, New York: Springer; 2011:3–16.

The routine postero-anterior chest X-ray (CXR) can be highly suggestive of specific ILD entities (Table 5), and previous CXRs, if available, should be sought to determine whether the disease is acute versus chronic. Other studies should not be overlooked; as specific examples, abdominal computed tomographic (CT) scans usually show a substantial portion of the lower lung regions and thorax, and cervical spine CT scans can show extensive areas of the upper chest and lungs.
Table 5

Thoracic imaging patterns

Imaging modality

Pattern

Consistent ILD diagnoses, mimics of ILD, and/or complications of ILD

Routine CXR

Hilar lymphadenopathy

Sarcoidosis, silicosis, CBD, infection, malignancy

Septal thickening

CHF, malignancy, infection, PVOD

Lower lung zone predominance

IPF, asbestosis, DIP, CTD, NSIP

Mid/upper lung zone predominance

Sarcoidosis, silicosis, acute HP, LCH, CBD, AS, chronic EP

Peripheral lung zone predominance

COP, chronic EP, IPF

Honeycomb change

IPF, asbestosis, chronic HP, sarcoidosis, fibrotic NSIP, CTD

Small nodules

Sarcoidosis, HP, infection

Cavitating nodules

PAG, mycobacterial infection, CA

Migratory or fluctuating opacities

HP, COP, DIP

Pneumothorax

PLCH, LAM, neurofibromatosis, TS

Pleural involvement

Asbestosis, CTD, acute HP, malignancy, sarcoidosis, Radiation fibrosis

Kerley B line prominence

Lymphangitic carcinomatosis, CHF

HRCT

Nodules

Sarcoidosis HP, CBD, pneumoconiosis, RA, malignancy

Septal thickening

Edema, malignancy, infection, drug toxicity, PVOD

Cyst formation

LAM, LCH, LIP, DIP, SS

Reticular lines

IPF, asbestosis, chronic EP, chronic HP, CTD, NSIP

Traction bronchiectasis

IPF, other end-stage fibrosis

Honeycomb change

IPF, chronic EP and HP, asbestosis, sarcoidosis

Ground-glass opacity

AIP, acute EP, PAP, chronic EP, COP, lymphoma, sarcoidosis, NSIP, infection, hemorrhage

AIP = acute interstitial pneumonia; AS = ankylosing spondylitis; CA = cancer; CBD = chronic beryllium diseases; COP = cryptogenic organizing pneumonia; CTD = connective tissue disease; DAH = diffuse alveolar hemorrhage; DM-PM = dermatopolymyositis; DIP = desquamative interstitial pneumonia; EP = eosinophilic pneumonia; HP = hypersensitivity pneumonitis; HPS = Hermansky-Pudlak syndrome; IPF = idiopathic pulmonary fibrosis; LAM = lymphangioleiomyomatosis; LCH = Langerhans cell histiocytosis; LIP = lymphoid interstitial pneumonia; NF = neurofibromatosis; NSIP = non-specific interstitial pneumonia; PAG = polyangiitis with granulomatosis; PAP = pulmonary alveolar proteinosis; P2 = auscultated pulmonic valve closure sound; PH = npulmonary hypertension; PVOD = pulmonary veno-occlusive disease; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; SS = Sjögren’s syndrome; TS = tuberous sclerosis.

Reprinted with permission from Interstitial Lung Disease: A Practical Approach. Meyer KC, Raghu G: Patient evaluation. Second Edition, New York: Springer; 2011:3–16.

Although the combination of history, physical examination, CXR, and other appropriate laboratory testing (peripheral blood tests and lung physiologic testing) may provide a likely diagnosis, additional testing is usually needed to reach a confident diagnosis of a specific ILD. HRCT of the thorax can provide invaluable information that strongly supports a specific diagnosis (Table 5) and may be diagnostic (e.g. typical changes of UIP) such that further testing with bronchoscopy or surgical lung biopsy is not required (Figure 1). Indeed, the HRCT has become a standard test for the evaluation of patients with possible ILD[4]. In general, a complete lack of pulmonary parenchymal changes on HRCT imaging virtually excludes a diagnosis of ILD, although ILD may rarely still be present with the lungs having microscopic involvement that does not reach the threshold for the detection of an abnormality that is detectable by HRCT. Multi-detector computed tomography (MDCT) scanning can scan the entire thorax with a single breath-hold maneuver and allow even better imaging than traditional HRCT, and an algorithmic approach can be utilized that facilitates differentiation among UIP, NSIP, and chronic HP patterns[5].
Figure 1

HRCT cross-sectional view showing a pattern of peripheral reticulation and honeycomb change that is diagnostic of the presence of UIP.

Invasive diagnostic procedures

Bronchoscopy and/or surgical lung biopsy may be required to make a confident diagnosis of a specific ILD (Figure 2). Bronchoscopy is generally a very safe procedure if performed by an experienced bronchoscopist[6], and the most serious potential complications are pneumothorax or excessive bleeding that may occur as a consequence of transbronchial biopsy (TBLBx). Bronchoalveolar lavage (BAL) can be readily performed, and the recently published, ATS Task Force Report on BAL for the diagnosis of ILD recommends using recently obtained HRCT imaging to choose an appropriate segment of the lung in which to perform BAL from a wedge position[7]. The right middle lobe or lingula of the left upper lobe are likely the best regions to perform lavage when diffuse disease is present, and areas with ground-glass opacification or profuse nodular change are more likely to provide useful diagnostic information (e.g. differential cell count of nucleated immune cells) than areas with extensive fibrosis. In addition to total and differential BAL cell counts, BAL fluid and sediment can be analyzed for infection or the presence of malignant cells, and the gross appearance of freshly retrieved BAL fluid may provide diagnosistic information (e.g. progressively increasing blood in sequential aliquots that is seen with diffuse alveolar hemorrhage or white-tan discoloration of the BAL fluid with rapidly settling tan sediment [due to gravity] that can be seen with pulmonary alveolar proteinosis). Significant BAL lymphocytosis or eosinophilia may provide strong support for a specific diagnosis when combined with imaging and clinical data, but routine determination of BAL lymphocyte subsets is unlikely to provide additional useful information[7, 8].
Figure 2

Suggested approach to the diagnosis of ILD. Abbreviations: BAL = bronchoalveolar lavage fluid; HRCT-high-resolution computed tomography; ILD = interstitial lung disease; VATS = video-assisted thorascopic surgery.

Endobronchial biopsy may provide useful information if endobronchial abnormalities are present (e.g. superficial nodules, mucosal ulceration). Similar to performing BAL, TBLBx is best performed away from areas of advanced fibrosis (as identified by HRCT). Multiple biopsies performed with an adequately sized forceps can provide good tissue sampling for some forms of ILD (e.g. sarcoidosis), but TBLBx is likely to be non-diagnostic when extensive/advanced fibrotic disease is present.

A surgical lung biopsy (SLB) obtained via video-assisted thoracic surgery (VATS) or open biopsy is likely to provide an excellent specimen (if properly performed) that shows a histopathologic pattern that can usually be considered to be definitively diagnostic of a specific disease entity. However, one must weigh risks and benefits when performing a SLB is considered, especially in frail elderly patients, patients with ventilatory compromise, patients with moderate to severe pulmonary hypertension, or patients with multiple co-morbidities. Open lung biopsy in patients with suspected ILD has approximately a 4.3% 30-day mortality rate, whereas VATS biopsy appears to be safer with an associated 30-day mortality that is somewhat lower than open biopsy but not negligible at approximately 2.1%[9]. Additionally, the highest mortality risk may occur in patients whose ultimate diagnosis is IPF[10, 11], and SLB in patients with IPF has been reported to trigger an acute exacerbation of IPF[12]. However, confirming the diagnosis and differentiating among specific forms of IIP may not be possible without performing SLB.

There is increasing awareness that an abnormal degree of gastroesophageal reflux (GER) combined with aspiration may play a significant role in the pathogenesis of a number of forms of ILD[13, 14]. GER disease (GERD) has been associated with IPF and with pulmonary fibrosis in patients with systemic sclerosis (scleroderma), and GER with aspiration may play a role in triggering and/or driving lung inflammation and fibrosis in IPF and scleroderma, and it has been linked to acute exacerbations in patients with IPF[15, 16]. Additionally, esophageal dysmotility may play a role in predisposition to aspiration and is usually found in patients with scleroderma and may be present in patients with other forms of CTD with associated ILD[14, 17, 18]. Esophageal manometry to detect esophageal functional abnormalities plus impedance/pH testing to detect and characterize GER may provide evidence of foregut functional abnormalities that may play a role in IPF and possibly CTD-ILD pathogenesis, and obtaining such information by placing esophageal probes may provide findings that support the employment of strategies to prevent or blunt pathologic GER[19]. More research is needed in this area to better understand the role of GER and microaspiration in the pathogenesis of IPF and other forms of ILD.

Making an accurate and confident diagnosis of a specific form of ILD

Patients with suspected ILD should have information from the history, physical examination, thoracic imaging, and other testing (e.g. peripheral blood tests, pulmonary function testing) carefully and thoughtfully reviewed to determine whether or not additional procedures are needed and whether such procedures are likely to be helpful in reaching a confident diagnosis. If one needs to obtain invasive testing (bronchoscopy with BAL and/or TBLBx, VATS biopsy), all findings should be reviewed (preferably in a multi-disciplinary fashion) to identify the ultimate diagnosis that best fits with the combination of clinical information, imaging, and invasive testing results[20]. Risks and potential benefit of invasive testing should be carefully considered, especially for frail, elderly patients.

Some specific combinations of clinical data with imaging results and other findings can strongly support specific ILD diagnoses. A younger patient with nodular changes along bronchovascular structures and bilateral hilar lymphadenopathy on HRCT imaging is highly likely to have a diagnosis of sarcoidosis, and the presence of a significant lymphocytosis on a BAL cell count determination would be highly supportive of this diagnosis. A patient with clearly abnormal autoimmune serologies and either a NSIP or UIP pattern on HRCT imaging is likely to have CTD-ILD and may have a specific CTD diagnosis such as rheumatoid arthritis or scleroderma that can be detected and confirmed via peripheral blood serologic testing. A patient with a significant exposure history to potential organic antigens (e.g. bird fancier or farmer) with a HRCT findings of upper lung field dominant centrilobular ground glass nodules, acute or subacute onset of symptoms (e.g. dyspnea, myalgias) is quite likely to have acute HP, and this diagnosis is strongly supported by the findings of significant BAL lymphocytosis. Similarly, a patient with such an exposure history plus a subacute or chronic symptom onset and a HRCT that shows ground glass opacities or fibrotic changes with extensive mosaic attenuation due to air-trapping is likely to have chronic HP. Lastly, an older patient who presents with subacute or chronic disease onset and has bibasilar Velcro crackles on chest auscultation is highly likely to have IPF as their specific ILD diagnosis, and this diagnosis can be confidently confirmed if the HRCT shows a typical UIP pattern (peripheral and basilar predominance of fibrotic changes with reticulation and honeycomb change (Figure 1) and very little or no ground glass opacities) and alternative etiologies are lacking (e.g. presence of CTD, asbestosis, drug reaction with fibrosis).

Key management decisions

Once a confident diagnosis has been reached, a plan to treat and monitor disease activity can be put in place (Table 6). Key management decisions include whether to administer pharmacologic agents, how the disease will be monitored to determine whether it has stabilized or improved versus progressive deterioration, whether a patient should be referred for lung transplantation, and whether the disease is end-stage and unlikely to respond to therapies such that providing supportive, palliative care is the best approach. A treatment plan should not only consist of pharmacologic agents that are prescribed to prevent progression and/or induce remission (if the specific disorder can respond to such) but should also include supportive therapies (e.g. supplemental oxygen if indicated, pulmonary rehabilitation), measures to relieve symptoms (e.g. cough, anxiety, depression, dyspnea) and treatment of co-morbid conditions (e.g. anemia, sleep-disordered breathing, GER, infectious complications).
Table 6

Management of the patient with ILD/IPF

▪ Establish a partnership with the patient to provide a patient-centered, personalized medicine care plan

▪ Provide supplemental oxygen if indicated (keep SpO2 ≥90%)

▪ Provide patients with:

  · During exertion

  · Nocturnal during sleep

 • Useful information concerning   the nature of their disease   and its prognosis

  · Continuous if indicated

 • Treatment options   accompanied by   thoughtful counseling

▪ Detect and treat co-morbidities and complications:

  · Enrollment in clinical trials

  · Gastroesophageal reflux    disease

  · Off-label therapies    (e.g. corticosteroids,    cytoxic drugs, other agents)

  · Cardiovascular disease

  · Lung transplantation

  · Drug toxicity (if treated)

  · Best supportive care

  · Sleep-disordered breathing

▪ Use disease-specific monitoring (for prognostication and treatment decisions)

  · Secondary pulmonary    hypertension

  · Pulmonary function testing    (FVC, DLCO, 6-MWT)

  · Metabolic bone disease    (osteopenia, osteoporosis)

  · Thoracic imaging

  · Anemia

  · Dyspnea score

  · Anxiety & depression

▪ Pulmonary rehabilitation (optimal exercise program, patient education)

▪ Maintain ideal body-mass index (weight reduction if obese, improved nutrition if cachectic)

▪ Vaccinations (pneumococcal vaccine, seasonal influenza, others as indicated)

DLCO = diffusion capacity of the lung for CO; FVC = forced vital capacity; 6-MWT = six-minute walk test; SpO2 = oxyhemoglobin percent saturation.

Measurements that can be made periodically to objectively assess changes in physiologic function over time include formal dyspnea assessment tools, the forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), and the 6-minute walk test (6-MWT) distance and oxyhemoglobin saturation change[2126]. The baseline FVC value has not been shown to correlate well with disease course for patients with IPF, but change in FVC over time has been show to correlate well with stable versus progressive disease with greater than 10% decline considered to be significant and indicative of disease progression[27, 28]. A decline of ≥15% in DLCO has also been correlated with disease progression in IPF[28], and declining 6-MWT distance or oxyhemoglobin saturation are also associated with disease progression[25, 29]. More recent analyses suggest that changes in FVC that are less than 10% may represent important clinical change[30], and using relative change rather than absolute change in FVC values may provide a better indication of clinical response[31]. In addition to its utility in diagnosis, HRCT can be scored for the extent/severity of fibrosis, and the fibrosis severity scoring has been shown to correlate with prognosis[32, 33]. However, the use of serial HRCT scanning has not been validated as a useful gauge of disease progression over time for IPF and presents a significant radiation risk to the patient. Biomarkers that reflect disease severity and correlate with prognosis have been reported for IPF[34, 35], but these have yet to be validated for use in the clinical setting.

Immunosuppressive anti-inflammatory agents are used to treat various forms of ILD (Table 7)[36, 37]. Although treatment of any form of ILD with immunosuppressive therapy is off-label in the U.S. and anti-inflammatory/immunosuppressive pharmacologic therapy has not been validated in placebo-controlled clinical trials, there is reasonably compelling evidence that the administration of agents such as corticosteroids is strongly associated with improvement or even clearing of lung pathology for many forms of ILD. This is particularly the case for disorders such as cryptogenic organizing pneumonia (COP), eosinophilic pneumonia, sarcoidosis, or cellular non-specific interstitial pneumonia (NSIP)[36].
Table 7

Therapies for select types of ILD

ILD type

Key features of immunopathogenesis

Current therapy*

Additional and/or alternative therapies

IPF

• Prominent fibroblast proliferation and matrix deposition

Supportive care

Anti-reflux therapy

• Patchy, temporally heterogeneous changes

Consider anti-reflux measures

N-acetylcysteine

• Architectural distortion of tissue

- Anti-reflux surgery

Clinical trials

• Epithelial injury, microvascular remodeling

- Acid suppressants (e.g. PPI)

(experimental)

• Variable inflammatory component (usually minimal/mild)

Pirfenidone (not approved in US)

• Areas of NSIP- and DIP-like change often present

• PH frequently present with advanced disease

Lung transplantation

Sarcoidosis

• Well-formed non-caseating granulomata in tissues

Observation (mild/stable disease)

Infliximab

• Extra-pulmonary disease may be present

Other IS agent

• May be asymptomatic; may resolve spontaneously without therapy

Corticosteroids (oral or inhaled)

Lung transplantation

Methotrexate

NSIP

• Homogeneous, diffuse involvement of the lung

Corticosteroids

Other IS drugs

• Histopathologic subtypes include cellular (prominent lymphocyte influx; best prognosis), mixed (cellular & fibrotic), & fibrotic (worst prognosis)

Mycophenolate

Lung transplantation

• Usually responsive to IS (less likely to respond if advanced fibrosis is established)

COP

• Prominent inflammatory cell infiltrate (↑ lymphocytes, neutrophils, and/or eosinophils can all be present)

Corticosteroids

Other IS drugs

Macrolides

• Usually responds to IS therapy; relapse frequently occurs

HP

• Prominent lymphocyte influx with formation of loose granulomata

Exposure cessation

Other IS drugs

• Can have appearance of cellular NSIP or OP

Corticosteroids

Lung transplantation

• Can progress to advanced fibrosis (and masquerade as IPF or fibrotic NSIP)

Eosinophilic pneumonia

• Prominent influx of eosinophils

Corticosteroids

Other IS drugs

• Usually responsive to IS therapy

CTD-ILD

• Lung histopathology can reveal NSIP (common), UIP (less common); other ILD (e.g. OP, DIP, RBILD – very uncommon)

Corticosteroids

Anti-reflux therapy

Mycophenolate

Lung transplantation

• PH often present (with or without ILD)

Other DMARD agent(s)

Treatment of PH

AIP/DAD

• Intense inflammation and alveolar damage

Corticosteroids

Cytotoxic drugs

• Hyaline membrane formation

• Prominent neutrophil influx early

  

*Therapies that are usually administered on the basis of expert opinion and clinical trial results; none have received US Food and Drug Administration approval for the indication of ILD/IPF (but pirfenidone is approved for treatment of IPF in some countries, and many DMARD agents are approved for treatment of CTD).

Abbreviations: AIP acute interstitial pneumonia, COP cryptogenic organizing pneumonia, CTD-ILD connective tissue disease-associated ILD, DAD diffuse alveolar damage, DIP desquamative interstitial pneumonia, DMARD disease-modifying anti-rheumatic drug, HP hypersensitivity pneumonitis, IPF idiopathic pulmonary fibrosis, ILD interstitial lung disease, IS immunosuppression, NSIP non-specific interstitial pneumonia, OP organizing pneumonia, PH pulmonary hypertension, RBILD respiratory bronchiolitis with interstitial lung disease.

When extensive fibrosis is present, such therapies may be less efficacious, especially for patients with IPF, for whom currently available immunosuppressive or anti-fibrotic therapies are not recommended[38]. However, some forms of CTD-associated ILD (NSIP or UIP pathologies) have been reported to respond to mycophenolate therapy, which also allowed a significant lowering of corticosteroid dosing[39]. If immunosuppressive agents are used to treat patients with ILD, treating clinicians should be adequately familiar with potential adverse reactions and drug-drug interactions, and guideline precautions (including recommended monitoring) should be followed[40]. Anti-fibrotic pharmacologic therapies are being increasingly brought to clinical trials[41, 42], and patients should be encouraged to enroll in clinical trials if they are found to have IPF or other forms of advanced ILD for which effective therapies have yet to be identified and clinical trials for their specific form of ILD are open to enrollment.

Treatment of IPF

The prognosis of IPF is generally poor, and the majority of patients have progressive loss of lung function and may suffer acute exacerbations with acceleration of lung function loss that often leads to death[43, 44]. Traditional therapies that were suggested to benefit patients with IPF included corticosteroids and cytotoxic drugs (e.g. azathioprine, cyclophosphamide)[45]. However, these agents have never been shown to have significant benefit in any adequately powered, prospective, randomized, placebo-controlled clinical trial. Furthermore, it was recently demonstrated that azathioprine, an agent that has been suggested to have efficacy for the treatment of IPF[4547], was associated with significant harm compared to placebo when administered to patients with IPF[48]. This observation triggered the termination of the azathioprine/N-acetylcysteine (NAC)/prednisone arm of the NIH-sponsored IPF PANTHER clinical trial when it became obvious that excess mortality and other complications occurred in this cohort versus the other study arms of either NAC alone or placebo. There are no treatment options for patients with IPF that have been approved by the U.S. Food and Drug Administration, and any pharmacologic treatment given in the US would be considered off-label.

Many new agents that target fibrogenesis have been evaluated in Phase 3 clinical trials (Table 8), but some of these agents (e.g. bosentan, macitentan, ambrisentan, interferons gamma and beta) have not shown benefit despite pre-clinical studies or phase 2 clinical trials that suggested potential efficacy. Indeed, there can be considerable inter-individual variability in genetic abnormalities that have predisposed an individual to develop the disease, in pathophysiologic characteristics of the disease process, and in responses to specific drugs. It should be recognized that a subset of patients that may benefit from a promising drug are very unlikely to be identified in a prospective, double-blind, randomized phase 3 clinical trial in which these patients are combined with a much larger number of enrolled subjects for whom the drug has little or no effect, and the conclusion may be reached that the drug lacks benefit despite its potential to help a subset of patients. Nonetheless, the results of some recently completed clinical trials suggest that pirfenidone[49, 50] or nintedanib (BIBF 1120)[51] may have a significant impact on disease progression versus placebo, and pirfenidone has been licensed and is clinically available in Japan, Europe, and Canada. Stem cell therapy, specifically the use of mesenchymal stem cells (MSC), has shown potential benefit in pre-clinical trials[52], and early results of a phase 1 clinical trial with adipose-derived MSC were recently reported[53].
Table 8

Pharmacotherapy for IPF: agents in current clinical trials

Agent

Target

Rationale

Pirfenidone

TGF-β, PDGF

Down-regulation of TGF-β-stimulated collagen synthesis and extracellular matrix accumulation and PDGF proliferative effects on fibroblasts

Tyrosine kinase inhibitors

Tyrosine kinase receptors

Inhibit fibrinogenic pathways by inhibiting receptor tyrosine kinase (RTK) binding by ligands (e.g. TGF-β, PDGF-B, CTGF, FGF, VEGF)

N-acetylcysteine

ROI (oxidant-antioxidant imbalance)

Replenish pulmonary glutathione stores and thereby antagonize signaling and tissue damaging effects of oxygen radicals (e.g. stimulatory effects of ROI on myofibroblasts)

Anti-TGF-β

TGF-β

Block TGF-β-induced fibroblast migration & proliferation, differentiation of myofibroblasts into fibroblasts, epithelial-mesenchymal transition, and resistance of myofibroblasts to apoptosis

Anti-CTGF

CTGF

Suppress fibroblast stimulation by CTGF

Anti-IL-13

IL-13

Inhibit induction of profibrotic cytokines (e.g. TGF-β, PDGF, IGF-1, PDGF, MMP-9)

Anti-LPA

Lysophosphatidic acid (LPA)

Prevent fibroblast recruitment into lung interstitium that can occur via the G protein-coupled LPA1 receptor

Anti-CCL2

CCL-2

Inhibit cell (e.g. lymphocytes, monocytes, fibrocytes) chemotaxis/influx to lung tissue and TGF-β expression

Anti-LOXL2

Lysyl oxidase-like protein-2 (LOXL-2)

Inhibit LOXL2-mediated fibroblast activation and deposition/accumulation of collagen

Plasma exchange, rituximab, steroids

Immune/inflammatory mediators

Suppress inflammation associated with an episode of acute exacerbation of IPF

Abbreviations: TGF-β transforming growth factor-β, TNF-α tumor necrosis factor-α, ROI reactive oxygen intermediates, CTGF connective tissue growth factor, PH pulmonary hypertension.

Comorbidities can have a significant impact on disease course and quality of life for patients with IPF and other fibrotic lung diseases[54, 55]. These include secondary pulmonary hypertension, coronary artery disease, venous thromboembolism, obstructive sleep apnea, coexistent emphysema, osteoporosis, diabetes mellitus, anxiety, and depression. Coronary artery disease is highly prevalent in patients with IPF[56, 57], and a significantly increased risk of developing primary lung cancer has been observed[58]. An increased risk of venous thromboembolism has also been observed[59], and sleep-disordered breathing is frequently present[60]. An IPFNet phase 3 clinical trial was performed to assess the effect of sildenafil in patients with idiopathic pulmonary fibrosis, but despite a trend toward improvement, a significant increase in 6MWT distance (the primary endpoint) was not attained[61], although a recent analysis of these data suggests that a subset of patients with right heart dysfunction may benefit from sildenafil therapy[62]. Similarly, anticoagulation, when given to disrupt the contribution of the coagulation cascade to the fibrotic process, provided no benefit and was associated with increased risk of significant adverse events[63].

An abnormal degree of GER, which is present in a majority of IPF patients and has been linked to the presence of pepsin and/or bile acids in BAL fluid[64], has also been considered to be an IPF-associated comorbidity. It has been suggested that reflux of foregut contents into the proximal esophagus via a dysfunctional lower esophageal sphincter (e.g. presence of a hiatal hernia) can predispose to (micro)aspiration, which may initiate and/or drive lung inflammation that can progress to pulmonary fibrosis in a susceptible individual, and accumulating evidence has linked GER with aspiration to IPF pathogenesis[13]. Use of medical therapy that inhibits acid production or having undergone a Nissen fundoplication has been associated with significantly improved survival for IPF patients[65], and an analysis of combined, placebo-arm cohorts from three IPFNet-sponsored studies has shown less FVC decline in subjects who were using acid-suppression therapy[16]. Additionally, high pepsin levels in BAL fluid have been linked to some cases of acute exacerbation of IPF[15], and a significantly reduced incidence of acute exacerbations of IPF was observed for subjects enrolled in combined placebo cohorts from the IPFNet phase 3 clinical trials if they were taking anti-reflux medication[66].

Lung transplantation

Lung transplantation is an accepted form of treatment for patients with ILD that is progressive, clearly leading to respiratory failure, and refractory to other therapies[66, 67]. The number of lung transplants performed for patients with IPF surpassed that for COPD in 2007, when IPF became the leading indication for lung transplants performed in the United States[68]. Lung transplantation is the only form of therapy that may improve quality of life and survival for patients with IPF, and 5-year survival following lung transplantation for IPF or other forms of pulmonary fibrosis is approximately 50%[69].

Key decisions that pertain to a potential lung transplant recipient include timing of referral, whether criteria are met that allow a patient to be listed for the procedure, and whether to perform a single versus bilateral lung transplant. International Society for Heart and Lung Transplantation (ISHLT) guidelines[70] state that referral to a transplant center should be considered when the diagnosis of IPF or fibrotic NSIP is made due to the relatively poor prognosis for patients with fibrotic lung disease and, especially, for those with IPF. These guidelines also recommend that transplantation thresholds for patients with IPF include DLCO <40% predicted, >10% decline in FVC, or desaturation below 88% on pulse oximetry during a 6MWT. Potential candidates must be evaluated very carefully to detect issues that are contraindications to being allowed to proceed to the point of being placed on a lung transplant waitlist[71], and if a candidate is placed on a waitlist, the type of transplant that the candidate could potentially receive (e.g. single only, bilateral only, single or bilateral) must be determined. Single lung transplantation is a simpler operation that may be better tolerated by patients with ILD, and bilateral lung transplant has not been shown to have a better survival outcome than single lung transplant for patients with ILD (or the subset of patients with IPF) at our center[72]. Although lung transplant recipients are at considerable risk to develop a considerable number of complications[71, 73], patients can achieve good quality of life and enhanced survival following lung transplant[69].

Future directions

Our understanding of the natural history and pathobiology of various forms of ILD continues to evolve, and classification systems, such as that for the IIPs[74], must be periodically revised to incorporate new knowledge. It is also clear from decades of research that the etiology and pathogenesis of IPF is highly complex[15, 75, 76] and likely involves an exposure stimulus (e.g. inhaled agents, aspirated gastrointestinal refluxate), genetic predisposition to consequent lung injury, and gene/genomics-directed aberrant repair responses that lead to sustained inflammation and matrix disruption/remodeling. Many clinical investigations with single agents have not shown benefit, and clinical trials with various agents have not simultaneously targeted multiple pathways (e.g. immune-mediated inflammatory responses plus abnormal myofibroblast behavior with progressive matrix deposition). Targeting only a single pathway or process rather than using a combination of agents may represent the “Achilles heel” of using monotherapy to treat IPF (and possibly other ILD with progressive fibrosis). While a single agent may have no significant impact on the clinical course of IPF, combination therapy may have an impact (e.g. combination therapy that includes an anti-fibrotic agent, immunomodulatory agent, anti-reflux therapy, and potent antioxidant). Selection of the appropriate endpoint measures for clinical trials may be key to identifying therapies that are clearly of benefit to patients with IPF[77, 78], and additional clinical research is much needed to identify effective therapies for IPF and other ILD associated with progressive fibrosis and early mortality. An improved understanding of the genetics and genomics of ILD will likely lead to the identification of new therapies that may have a significant treatment effect that relieves symptoms and restores quality of life for patients with significant, progressive ILD, but such therapies should have minimal risk of precipitating adverse reactions that can abrogate the benefits of pharmacotherapy.

Conclusions

The diagnosis and treatment of the various types of ILD present a considerable challenge to clinicians. Nonetheless, a comprehensive clinical evaluation combined with appropriate imaging and diagnostic procedures can achieve a confident diagnosis of a specific type of ILD, and invasive testing with bronchoscopy or SLB may not be required. Treatment of ILD entities that are characterized by lung inflammation without the presence of extensive fibrosis can be quite successful when anti-inflammatory immunosuppressive agents are administered. However, when extensive fibrosis has become established, such therapies may have little or no impact on disease progression, especially in patients with IPF. Patients with progressive disease for which effective therapies are lacking should be encouraged to enroll in clinical trials if such are available, and lung transplantation can be considered for appropriate candidates. The diagnosis and treatment of comorbid conditions may also provide significant benefit to patients, and treating clinicians should focus on optimizing quality of life and symptom palliation for patients with advanced, progressive disease.

Abbreviations

ATS: 

American thoracic society

BAL: 

Bronchoalveolar lavage

COPD: 

Chronic obstructive pulmonary disease

CT: 

Computed tomography

CTD: 

Connective tissue disease

CTD-ILD: 

Connective tissue disease-associated interstitial lung disease

CXR: 

Chest x-ray

DLCO: 

Diffusion capacity of the lung for carbon monoxide

FVC: 

Forced vital capacity

GER: 

Gastroesophageal reflux

GERD: 

Gastroesophageal reflux disease

HP: 

Hypersensitivity pneumonitis

HRCT: 

High-resolution computed tomography

IIP: 

Idiopathic interstitial pneumonia

ILD: 

Interstitial lung disease

IPF: 

Idiopathic pulmonary fibrosis

ISHLT: 

International society for heart and lung transplantation

MDCT: 

Multi-detector computed tomography

MSC: 

Mesenchymal stem cells

6-MWT: 

6-minute walk test

NAC: 

N-acetylcysteine

NSIP: 

Non-specific interstitial pneumonia

SLB: 

Surgical lung biopsy

TBLBx: 

Transbronchial lung biopsy

UIP: 

Usual interstitial pneumonia

VATS: 

Video-assisted thorascopic surgery.

Declarations

Acknowledgments

Supported in part by the George and Julie Mosher Pulmonary Research Fund

Authors’ Affiliations

(1)
Department of Medicine, University of Wisconsin School of Medicine and Public Health

References

  1. Meyer KC, Raghu G: Patient evaluation. In Interstitial Lung Disease: A Practical Approach. Second edition. Edited by: Baughman RP, Du Bois RM. New York: Springer; 2011:3–16.Google Scholar
  2. Meyer KC: Interstitial lung disease in the elderly: pathogenesis, diagnosis and management. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28: 3–17.Google Scholar
  3. Swigris JJ, Brown KK, Flaherty KR: The idiopathic interstitial pneumonias and connective tissue disease-associated interstitial lung disease. Curr Rheum Rev 2010, 6: 91–98. 10.2174/157339710791330731View ArticleGoogle Scholar
  4. Kanne JP: Interstitial lung disease (ILD): imaging finding, and the role of imaging in evaluating the patient with known or suspected ILD. Semin Roentgenol 2010, 45: 3. 10.1053/j.ro.2009.09.001View ArticleGoogle Scholar
  5. Hodnett PA, Naidich DP: Fibrosing Interstitial Lung Disease. A Practical High-Resolution Computed Tomography-based Approach to Diagnosis and Management and a Review of the Literature. Am J Respir Crit Care Med 2013, 188: 141–149. 10.1164/rccm.201208-1544CIView ArticleGoogle Scholar
  6. Joos L, Patuto N, Chhajed PN, Tamm M: Diagnostic yield of flexible bronchoscopy in current clinical practice. Swiss Med Wkly 2006, 136: 155–159.Google Scholar
  7. Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, Du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, Rottoli P, Saltini C, Selman M, Strange C, Wood B: An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012, 185: 1004–1014. 10.1164/rccm.201202-0320STView ArticleGoogle Scholar
  8. Meyer KC, Raghu G: Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Eur Respir J 2011, 38: 761–769. 10.1183/09031936.00069509View ArticleGoogle Scholar
  9. Nguyen W, Meyer KC: Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacy. Sarcoidosis Vasc Diffuse Lung Dis 2013, 30: 3–16.Google Scholar
  10. Utz JP, Ryu JH, Douglas WW, Hartman TE, Tazelaar HD, Myers JL, Allen MS, Schroeder DR: High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 2001, 17: 175–179. 10.1183/09031936.01.17201750View ArticleGoogle Scholar
  11. Park JH, Kim DK, Kim DS, Koh Y, Lee SD, Kim WS, Kim WD, Park SI: Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia. Eur J Cardiothorac Surg 2007, 31: 1115–1119. 10.1016/j.ejcts.2007.02.035View ArticleGoogle Scholar
  12. Kondoh Y, Taniguchi H, Kitaichi M, Yokoi T, Johkoh T, Oishi T, Kimura T, Nishiyama O, Kato K, Du Bois RM: Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med 2006, 100: 1753–1759. 10.1016/j.rmed.2006.02.002View ArticleGoogle Scholar
  13. Raghu G, Meyer KC: Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? Eur Respir J 2012, 39: 242–245. 10.1183/09031936.00211311View ArticleGoogle Scholar
  14. Meyer KC, Raghu G: GER and aspiration in interstitial lung disease. In Gastroesophageal Reflux and the Lung. Edited by: Meyer KC, Raghu G. New York: Springer; 2012:175–198.View ArticleGoogle Scholar
  15. Lee JS, Song JW, Wolters PJ, Elicker BM, King TE Jr, Kim DS, Collard HR: Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012, 39: 352–358. 10.1183/09031936.00050911View ArticleGoogle Scholar
  16. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G, for the IPFnet Investigators: Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomized controlled trials. Lancet Respiratory Medicine 2013, 1: 369–376. 10.1016/S2213-2600(13)70105-XView ArticleGoogle Scholar
  17. Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G, Negrini S, Indiveri F, Tutuian R, Savarino V, Ghio M: Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009, 179: 408–413. 10.1164/rccm.200808-1359OCView ArticleGoogle Scholar
  18. Soares RV, Forsythe A, Hogarth K, Sweiss NJ, Noth I, Patti MG: Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. Arq Gastroenterol 2011, 48: 91–97. 10.1590/S0004-28032011000200002View ArticleGoogle Scholar
  19. Oelschlager BK, Chang L, Pope CE 2nd, Pellegrini CA: Typical GERD symptoms and esophageal pH monitoring are not enough to diagnose pharyngeal reflux. J Surg Res 2005, 128: 55–60. 10.1016/j.jss.2005.02.021View ArticleGoogle Scholar
  20. Flaherty KR, King TE Jr, Raghu G, Lynch JP 3rd, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ: Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004, 170: 904–910. 10.1164/rccm.200402-147OCView ArticleGoogle Scholar
  21. Swigris JJ, Yorke J, Sprunger DB, Swearingen C, Pincus T, Du Bois RM, Brown KK, Fischer A: Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respir Med 2010, 104: 1350–1355. 10.1016/j.rmed.2010.03.027View ArticleGoogle Scholar
  22. Swigris JJ, Han M, Vij R, Noth I, Eisenstein EL, Anstrom KJ, Brown KK, Fairclough D: The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med 2012, 106: 1447–1455. 10.1016/j.rmed.2012.06.018View ArticleGoogle Scholar
  23. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK: Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168: 538–542. 10.1164/rccm.200211-1311OCView ArticleGoogle Scholar
  24. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, Du Bois RM, Hansell DM: Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003, 167: 962–969. 10.1164/rccm.2111053View ArticleGoogle Scholar
  25. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP 3rd, Martinez FJ: Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2005, 168: 1084–1090.View ArticleGoogle Scholar
  26. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, Lama V, Kazerooni EA, Gross BH, Toews GB, Martinez FJ: Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute walk test. Am J Respir Crit Care Med 2006, 174: 803–809. 10.1164/rccm.200604-488OCView ArticleGoogle Scholar
  27. King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA: Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005, 127: 171–177. 10.1378/chest.127.1.171View ArticleGoogle Scholar
  28. Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, Kazerooni EA, Chughtai AR, Lagstein A, Myers JL, Murray S, Toews GB, Martinez FJ, Flaherty KR: Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011, 38: 176–183. 10.1183/09031936.00114010View ArticleGoogle Scholar
  29. Du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr: Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011, 183: 1231–1237. 10.1164/rccm.201007-1179OCView ArticleGoogle Scholar
  30. Du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU: Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011, 184: 1382–1389. 10.1164/rccm.201105-0840OCView ArticleGoogle Scholar
  31. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE Jr, Ryu JH, Collard HR: Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012, 67: 407–411. 10.1136/thoraxjnl-2011-201184View ArticleGoogle Scholar
  32. Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE Jr, Bradford WZ, Schwartz DA, Richard Webb W, Idiopathic Pulmonary Fibrosis Study Group: High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005, 172: 488–493. 10.1164/rccm.200412-1756OCView ArticleGoogle Scholar
  33. Edey AJ, Devaraj AA, Barker RP, Nicholson AG, Wells AU, Hansell DM: Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Eur Radiol 2011, 21: 1586–1593. 10.1007/s00330-011-2098-2View ArticleGoogle Scholar
  34. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO, Klesen M, Zhang Y, Gibson KF: Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J RespirCrit Care Med 2012, 185: 67–76. 10.1164/rccm.201101-0058OCView ArticleGoogle Scholar
  35. Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS: Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest 2013, 143: 1422–1429. 10.1378/chest.11-2735View ArticleGoogle Scholar
  36. Kim R, Meyer KC: Therapies of interstitial lung disease—past, present, and future. Therapeutic Advances Respir Dis 2008, 2: 319–338. 10.1177/1753465808096948View ArticleGoogle Scholar
  37. Meyer KC, Bierach J: Immunosuppressive therapy for autoimmune lung diseases. Immunol Allergy Clin North Am 2012, 32: 633–639. 10.1016/j.iac.2012.07.001View ArticleGoogle Scholar
  38. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis, et al.: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183: 788–824. 10.1164/rccm.2009-040GLView ArticleGoogle Scholar
  39. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, Huie TJ, Krishnamoorthy M, Meehan RT, Olson AL, Solomon JJ, Swigris JJ: Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013, 40: 640–646. 10.3899/jrheum.121043View ArticleGoogle Scholar
  40. Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, Culver D, Harrod CG, Hayney MS, Highland KB, Limper AH, Patrick H, Strange C, Whelan T: Executive summary: monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 142: 1284–1288. 10.1378/chest.12-1075View ArticleGoogle Scholar
  41. Lota HK, Wells AU: The evolving pharmacotherapy of pulmonary fibrosis. Expert Opin Pharmacother 2013, 14: 79–89. 10.1517/14656566.2013.758250View ArticleGoogle Scholar
  42. Adamali HI, Maher TM: Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Design Develop Ther 2013, 6: 261–272.Google Scholar
  43. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ, Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators: Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007, 176: 636–643. 10.1164/rccm.200703-463PPView ArticleGoogle Scholar
  44. Kim DS: Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir Res 2013, 14: 86. Epub ahead of print 10.1186/1465-9921-14-86View ArticleGoogle Scholar
  45. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161: 646–664.View ArticleGoogle Scholar
  46. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Hutchinson J, Pardee NE, Winterbauer RH: Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991, 144: 291–296. 10.1164/ajrccm/144.2.291View ArticleGoogle Scholar
  47. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M, IFIGENIA Study Group: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353: 2229–2242. 10.1056/NEJMoa042976View ArticleGoogle Scholar
  48. Idiopathic Pulmonary Fibrosis Clinical Research Network: Prednisone, azathioprine, and nacetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366: 1968–1977.View ArticleGoogle Scholar
  49. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T, Pirfenidone Clinical Study Group in Japan: Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35: 821–829. 10.1183/09031936.00005209View ArticleGoogle Scholar
  50. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, Du Bois RM, CAPACITY Study Group: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377: 1760–1769. 10.1016/S0140-6736(11)60405-4View ArticleGoogle Scholar
  51. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Klüglich M, Du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365: 1079–1087. 10.1056/NEJMoa1103690View ArticleGoogle Scholar
  52. Toonkel RL, Hare JM, Matthay MA, Glassberg MK: Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. Am J Respir Crit Care Med 2013, 188: 133–140. 10.1164/rccm.201207-1204PPView ArticleGoogle Scholar
  53. Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D, Antoniadis A, Froudarakis M, Kolios G, Bouros D: A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med 2013, 11: 171. 10.1186/1479-5876-11-171View ArticleGoogle Scholar
  54. King TE Jr, Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet 2011, 378: 1949–1961. 10.1016/S0140-6736(11)60052-4View ArticleGoogle Scholar
  55. King C, Nathan SD: Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Curr Opin Pulm Med 2013, 19: 466–473. 10.1097/MCP.0b013e328363f460View ArticleGoogle Scholar
  56. Kizer JR, Zisman DA, Blumenthal NP, Kotloff RM, Kimmel SE, Strieter RM, Arcasoy SM, Ferrari VA, Hansen-Flaschen J: Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med 2004, 164: 551–556. 10.1001/archinte.164.5.551View ArticleGoogle Scholar
  57. Nathan SD, Basavaraj A, Reichner C, Shlobin OA, Ahmad S, Kiernan J, Burton N, Barnett SD: Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 2010, 104: 1035–1041. 10.1016/j.rmed.2010.02.008View ArticleGoogle Scholar
  58. Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, Nakamura Y, Inui N, Nakamura H, Chida K: Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 2009, 14: 723–728. 10.1111/j.1440-1843.2009.01547.xView ArticleGoogle Scholar
  59. Sprunger DB, Olson AL, Huie TJ, Fernandez-Perez ER, Fischer A, Solomon JJ, Brown KK, Swigris JJ: Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J 2012, 39: 125–132. 10.1183/09031936.00041411View ArticleGoogle Scholar
  60. Lancaster LH, Mason WR, Parnell JA, Rice TW, Loyd JE, Milstone AP, Collard HR, Malow BA: Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009, 136: 772–778. 10.1378/chest.08-2776View ArticleGoogle Scholar
  61. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW, Idiopathic Pulmonary Fibrosis Clinical Research Network: A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010, 363: 620–628.View ArticleGoogle Scholar
  62. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ, IPFnet Investigators: Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013, 143: 1699–1708. 10.1378/chest.12-1594View ArticleGoogle Scholar
  63. Noth I, Anstrom KJ, Calvert SB, De Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA, Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012, 186: 88–95. 10.1164/rccm.201202-0314OCView ArticleGoogle Scholar
  64. Savarino E, Carbone R, Marabotto E, Furnari M, Sconfienza L, Ghio M, Zentilin P, Savarino V: Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J 2013, 42: 1322–1331. 10.1183/09031936.00101212View ArticleGoogle Scholar
  65. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE Jr, Collard HR: Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184: 1390–1394. 10.1164/rccm.201101-0138OCView ArticleGoogle Scholar
  66. Kotloff RM, Thabut G: Lung transplantation. Am J Respir Crit Care Med 2011, 184: 159–171. 10.1164/rccm.201101-0134CIView ArticleGoogle Scholar
  67. Meyer KC: Lung transplantation. F1000Prime Rep 2013, 5: 16.View ArticleGoogle Scholar
  68. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. 2011. . Accessed 02 Sep 2012 http://srtr.transplant.hrsa.gov/annual_reports/2010/
  69. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI: The registry of the international society for heart and lung transplantation: twenty-eighth adult lung and heart-lung transplant report–2011. J Heart Lung Transplant 2011, 30: 1104–1122. 10.1016/j.healun.2011.08.004View ArticleGoogle Scholar
  70. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al.: International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the pulmonary scientific council of the international society for heart and lung transplantation. J Heart Lung Transplant 2006, 25: 745–755. 10.1016/j.healun.2006.03.011View ArticleGoogle Scholar
  71. McCartney J, Meyer KC: Optimizing post-transplant outcomes in lung transplantation. Expert Rev Respir Med 2008, 2: 183–199. 10.1586/17476348.2.2.183View ArticleGoogle Scholar
  72. De Oliveira NC, Osaki S, Maloney JD, Cornwell RD, Meyer KC: Lung transplant for interstitial lung disease: outcomes for single versus bilateral lung transplantation. Interact Cardiovasc Thor Surg 2012, 14: 263–267. 10.1093/icvts/ivr085View ArticleGoogle Scholar
  73. Todd JL, Palmer SM: Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest 2011, 140: 502–508. 10.1378/chest.10-2838View ArticleGoogle Scholar
  74. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, ATS/ERS Committee on Idiopathic Interstitial Pneumonias, et al.: An official american thoracic society/european respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013, 188: 733–748. 10.1164/rccm.201308-1483STView ArticleGoogle Scholar
  75. Günther A, Korfei M, Mahavadi P, von der Beck D, Ruppert C, Markart P: Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev 2012, 21: 152–160. 10.1183/09059180.00001012View ArticleGoogle Scholar
  76. Todd NW, Luzina IG, Atamas SP: Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 2012, 5: 11. 10.1186/1755-1536-5-11View ArticleGoogle Scholar
  77. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK: Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012, 185: 1044–1048. 10.1164/rccm.201201-0006PPView ArticleGoogle Scholar
  78. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, IPFnet investigators: Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res 2013, 14: 73. 10.1186/1465-9921-14-73View ArticleGoogle Scholar

Copyright

© Meyer; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.